TrialThe Journal of clinical investigation1999

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions.

W L Trepicchio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.